In the Media

BioMed X Institute: BioMed X Launches New US Institute in New Haven, CT

FinanzNachrichten

BioMed X, an independent research institute founded in Heidelberg, Germany, has expanded its operations with the opening of a new institute in the United States. Located in New Haven, CT, in the vicinity of Yale University, the new facilities are part of the Elm City Bioscience Center.

BIOMED X LAUNCHES NEW US INSTITUTE IN NEW HAVEN, CT

Yale Ventures

Yale Ventures Managing Director Josh Geballe took part in the opening ceremony on Tuesday and expressed his excitement for the collaboration potential that BioMed X brings to New Haven: “Yale is committed to global partnerships that foster innovation. We warmly welcome BioMed X to our bio-ecosystem and are looking forward to future collaborations.”

BioMed X Launches New US Institute in New Haven, CT

Yahoo! Finance

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

PharmiWeb

The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

MarketWatch

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

FinanzNachrichten

German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

Yahoo! Finance

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.

BioMed X and AbbVie Extend Research Collaboration in the US

Street Insider

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

The BioMed X Institute: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

FinanzNachrichten

“We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases,” said Carine Boustany, PhD, Global Head of Immunology & Respiratory Diseases Research, Boehringer Ingelheim.

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

Yahoo! Finance

XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration with Boehringer Ingelheim

PharmiWeb

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

WebDisclosure

BioMed X Institute’s new XSeed Labs research team starts activity in the U.S. in collaboration with Boehringer Ingelheim.

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

BioSpace

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

New Immuno-Oncology Research Project in Partnership With Merck KGaA Starts at the BioMed X Institute in Heidelberg

FinanzNachrichten

Dr. Semih Akincilar, the scientist leading this project, explains: “Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment.”

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

Yahoo! Finance

“With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology,” said Christian Tidona, Founder and Managing Director of the BioMed X Institute.

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

BioSpace

The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.

Israeli startup to use AI to transform antibody discovery, design

Israel’s AION Labs announced last week the launch of CombinAble.AI, a startup focused on improving antibody design to speed up the development of better therapeutics.

AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development

Yahoo! Finance

New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases

AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development

PR Newswire

New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

PharmiWeb

Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Healthcare Industry Baden Württemberg (powered by BioPro)

BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON). The main objective of…